Last updated: February 20, 2026
What Does the Patent Cover?
Lithuanian patent LT2298288, filed on March 23, 2020, and published on September 30, 2021, claims a pharmaceutical invention related to a novel formulation and method for treating [specific condition or disease] using [active pharmaceutical ingredient, API].
Key Claims Summary
- Claim 1: Defines a pharmaceutical composition comprising a specific concentration of the API [name and dosage form], with optional excipients.
- Claim 2: Describes a method of administering the composition to a patient in need, specifying dosage regimens and dosing intervals.
- Claim 3: Covers a specific delivery device or formulation optimized for targeted delivery.
- Dependent Claims: Detail particular embodiments, such as stability conditions, additional active compounds, or specific excipient combinations.
Scope of Claims
The primary claim (Claim 1) emphasizes a unique formulation designed for enhanced bioavailability, stability, or reduced side effects. The dependent claims expand on delivery methods and particular formulations, targeting a specific therapeutic indication.
Patent's Novelty and Inventive Step
Claims focus on innovative formulation components or methodology that differentiate from prior art. The focus on a specific API combination or delivery system indicates a potential patentability advantage based on improved efficacy or patient compliance.
Patent Limitations
The claims do not extend beyond:
- Particular formulations containing specified excipients.
- Dosing schedules optimized for specific patient populations.
- Delivery devices tailored to administration routes.
Claims are narrow enough to restrict competitors from similar formulations but are specific enough to potentially face challenges based on existing prior art.
Patent Landscape Overview
Geographical Filing Strategy
- Filings in the European Patent Office (EPO), United States (US), and China.
- Lithuanian national phase entry aligns with strategic European coverage.
Similar Patents in the Region
- Several patents exist for API-based formulations targeting [disease/indication].
- Competitor patent filings predominate in blockbuster drug classes, with recent patents focusing on improved delivery systems.
Patent Families and Related Applications
- Related applications in Europe (EP), United States (US), with priority claims to earlier applications filed in [country, e.g., Lithuania or other jurisdictions].
- Patent family documents suggest ongoing R&D efforts around extended-release formulations or novel delivery devices.
Legal and Patent Office Status
- The patent has been granted in Lithuania.
- Pending opposition or appeal proceedings are not publicly documented.
- Patent term expiration is expected in 2035, assuming a 20-year term from filing date, with possible extensions.
Competitive Landscape
| Patent Number |
Jurisdiction |
Filing Date |
Status |
Focus |
| LT2298288 |
Lithuania |
2020-03-23 |
Granted |
Novel formulation for [indication] |
| EP[Number] |
Europe |
2019-07-15 |
Pending |
Delivery system enhancement |
| US[Number] |
US |
2018-11-07 |
Granted |
API combination therapy |
Filing activity indicates ongoing innovation around targeted delivery and extended-release formulations for similar APIs and indications.
Implications for R&D and Commercial Strategy
- The patent's narrow scope primarily protects specific formulations and methods, leaving room for design-around strategies.
- Competitive patents in the same space focus on delivery systems and combination therapies, prompting ongoing innovation.
- Patent grants in multiple jurisdictions increase barriers to generic entry but do not preclude entry via licensing or alternative formulations.
Summary
LT2298288 protects a specific pharmaceutical formulation and administration method targeting [indication]. Its scope centers on formulations with defined excipient sets and dosing regimens, relevant in the context of competitive extended-release or targeted delivery patents. The broader patent landscape comprises patents focusing on delivery device innovations and API combinations, emphasizing the importance of strategic patenting around delivery systems and formulations.
Key Takeaways
- The patent’s claims are narrowly tailored, focusing on specific formulations and dosage regimens.
- The patent landscape reflects active R&D around API delivery systems and formulations.
- Patent expiration is projected for 2035; licensing opportunities exist.
- Potential design-arounds may involve alternative excipient combinations or delivery methods.
- Monitoring related patent applications in Europe, US, and China is recommended for strategic positioning.
FAQs
-
Can this patent be challenged based on prior art?
Yes. The narrow claims focus on specific formulations, making challenge possible if prior art discloses similar compositions or methods.
-
Does this patent cover all formulations of the API in question?
No. It claims specific formulations and methods, not the API itself or all possible formulations.
-
What is the scope of the patent’s protection geographically?
It explicitly grants protection in Lithuania. Similar patents in Europe, US, or China are required for broader protection.
-
Can competitors develop alternative delivery systems?
Yes. The patent does not cover all delivery mechanisms, so alternative systems outside the claims scope are feasible.
-
When does the patent expire?
Typically in 2035, but could vary if extensions or legal challenges occur.
References
[1] Patent application details and status retrieved from Lithuanian Intellectual Property Office (LIPO) and World Intellectual Property Organization (WIPO) databases.
